A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells

YU ZHANG1*, JIE LUO2*, XIAO WANG3, HAN-LIN WANG1, XIU-LING ZHANG1, TING-QING GAN2, GANG CHEN1 and DIAN-ZHONG LUO1

Departments of 1Pathology and 2Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021; 3Department of Orthopedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250012, P.R. China

Received September 17, 2016; Accepted October 13, 2017

DOI: 10.3892/ol.2018.8105

Abstract. Long non-coding RNA HOXA11 antisense RNA (HOXA11-AS) has been previously reported to be involved in the tumorigenesis and progression of ovarian cancer and glioma. However, the function of HOXA11-AS in lung cancer remains unclear. Following the knockdown of HOXA11-AS in A549 cells, a microarray analysis was performed in order to detect the differences in microRNA (miRNA/miR) profiles. Subsequently, miR-642b-3p was selected for further analysis. Four miRNA target prediction algorithms were used to identify potential target genes of miR-642b-3p. Bioinformatics analyses, including Gene Ontology (GO), Kyoto Encyclopaedia of Genes and Genomes, protein-protein interactions (PPIs) and network analysis, were performed to investigate the potential functions, pathways and networks of the target genes. Furthermore, the differential expression of miR-642b-3p and its target genes between normal lung and non-small cell lung cancer (NSCLC) tissues was verified using The Cancer Genome Atlas (TCGA) database. Six target genes [zinc finger protein 350, heterogeneous nuclear ribonucleoprotein U, high mobility group box 1, phosphodiesterase 4D (PDE4D), synaptotagmin binding cytoplasmic RNA interacting protein and basic helix-loop-helix family member B9] of miR-642b-3p were predicted using all 4 algorithms. It was revealed that miR-642b-3p was overexpressed in adenocarcinoma and squamous cell carcinoma tissues compared with non-cancerous lung tissues based on the TCGA database. From the 6 target genes, PDE4D was downregulated in lung adenocarcinoma and squamous cell carcinoma tissues, and a weak negative correlation between HOXA11-AS and PDE4D was identified. The area under the curve of PDE4D was 0.905 [95% confidence interval (CI), 0.879-0.931] for patients with lung adenocarcinoma and 0.665 (95% CI, 0.606-0.725) for patients with squamous cell carcinoma. Additionally, GO analysis of the target genes revealed that miR-642b-3p was specifically involved in complex cellular pathways. The target gene RAN binding protein 2 possessed the highest degree of interactions in the PPI network (degree=40). It was hypothesized that HOXA11-AS may have a function in NSCLC by regulating the expression of miR-642b-3p and PDE4D, which laid the foundation for the further elucidation of the potential molecular mechanisms of NSCLC.

Introduction

Lung cancer has a substantial mortality rate and the incidence of lung cancer has been increasing gradually (1-5). Based on histological type, lung cancer may be divided into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). From all types of lung cancer, 80-85% are classified as NSCLC (6,7). Additionally, in >70% of newly diagnosed NSCLC cases, the disease is at an advanced stage, and the 5-year survival rate of patients with NSCLC is only 16% (8). Hence, it is imperative to identify potential molecular mechanisms of NSCLC tumorigenesis and progression.

Non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and microRNAs (miRNA/miR), have been demonstrated to function differently in different types of cancer. Different ncRNAs in the same cancer may have different underlying functions (9,10). Previous studies demonstrated that ncRNAs are extensively involved in the tumorigenesis and progression of NSCLC (11,12). Various lncRNAs have been confirmed to have significant functions in epigenetic gene regulation, transcriptional regulation...
or disease development (13-16). It is of note that IncRNAs may regulate the transcription of corresponding genes by combining with polymerases or transcription factors due to their pervasive distribution in the nucleus (15,17). Previous studies have revealed that IncRNAs may regulate miRNA expression in lung cancer. With regards to the interplay between IncRNAs and miRNAs during tumorigenesis and progression, the competing endogenous RNA (ceRNA) hypothesis has attracted attention (18,19). The ceRNA hypothesis posits that IncRNAs function as molecular sponges for miRNAs and functionally liberate the targeted miRNAs regulated by the aforementioned miRNAs (20-22). For example, the IncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) may function as a ceRNA for miR-377-3p, and NEAT1 promotes NSCLC progression by regulating the expression of miR-377-3p (23). The IncRNA colon cancer-associated transcript 1 (non-protein coding) reduced miR-218 levels via the use of BMI1 proto-oncogene, polycomb ring finger to promote cell cycle transition in cigarette smoke extract-induced lung carcinogenesis (24). The IncRNA urothelial cancer associated one performed oncogenic functions in NSCLC by targeting miR-193a-3p (25). Furthermore, IncRNAs may co-express with microRNA in diseases. For example, Keniry et al (26) revealed that IncRNA H19, imprinted maternally expressed transcript (non-protein coding) may function as the pre-miRNA of miR-675, and they may interplay to suppress growth. Furthermore, miRNAs regulate the expression of their target transcripts by binding to the 3'-untranslated region (3'-UTR) (27-32). For example, Huang et al (33) revealed that miR-186 may suppress the cell proliferation and metastasis of NSCLC by targeting mitogen-activated protein kinase kinase 2. Lu et al (34) revealed that miR-541-3p may reverse cancer progression by directly targeting TGFβ induced factor homeobox 2 in NSCLC. Hence, the further investigation of miRNA profiling associated with IncRNAs in NSCLC is useful in order to identify novel targeted therapeutic strategies.

In the present study, a microarray analysis was performed to verify the differential expression of miRNAs between the RNA interference (RNAi) and control samples according to the fold change filtering (fold change ≥1.5 or ≤1) and the P-value (P<0.05). The five most downregulated miRNAs were selected (miR-1264, miR-337-3p, miR-302c-5p, miR-642b-3p and miR-3621). Then, based on original data from The Cancer Genome Atlas (TCGA), miR-642b-3p was selected for further analysis. Four miRNA target prediction algorithms were used to identify the potential target genes of miR-642b-3p. Bioinformatics analysis, including Gene Ontology (GO), the Kyoto Encyclopaedia of Genes and Genomes (KEGG), protein-protein interactions (PPIs) and network analysis were performed in order to investigate the potential functions, pathways and networks of the target genes (35-38). Additionally, the expression of miR-642b-3p and its targeted genes [zinc finger protein 350 (ZNF350), heterogeneous nuclear ribonucleoprotein U (HNRNPU), high mobility group box 1 (HMGB1), phosphodiesterase 4D (PDE4D), synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP), basic helix-loop-helix family member B9 (BHLHB9)] in NSCLC was analysed based on original data from TCGA database.

Materials and methods

Microarray analysis and the knockdown of HOXA11 antisense RNA (HOXA11-AS) in the NSCLC cell line A549. The A549 human NSCLC cell line was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), and cultivated in a humidified atmosphere of 5% CO₂ at 37°C with 10% heat-inactivated foetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The A549 NSCLC cell line was transfected with HOXA11-AS small interfering RNA and the subsequent experiments were performed at least 72 h following transfection. Lipofectamine™ 2000 (cat no. 11668-019; Invitrogen; Thermo Fisher Scientific, Inc.) was used for transfection, according to the manufacturer’s protocol. A microarray analysis was performed in order to verify the differential expression of miR-642b-3p between the RNAi and control samples according to fold-change filtering (fold-change ≥1.5 or ≤1) and P-value (P<0.05).

miRNA target prediction. Four miRNA target prediction algorithms were utilized to predict the potential target genes of miR-642b-3p. The four corresponding prediction algorithms were miRDB (version 4.0, http://www.mirdb.org/) (39,40), mirTarBase (http://miirtarbase.mbc.nctu.edu.tw/) (41), TargetScan (version 6.2; http://www.targetscan.org/) (42) and DIANA-microT (version v4.0; http://www.microrna.gr/microT) (43,44). Candidate genes were identified and compared with Venn diagrams (http://bioinformatics.psb.ugent.be/webtools/Venn/).

GO and pathway analysis and construction of a PPI network.

To elucidate the potential functions of the target genes, GO and KEGG pathway analyses were conducted at the biological process (BP), cellular component (CC) and molecular function (MF) levels, as previously described (45). The enrichment of potential target genes was further analysed using the Database for Annotation, Visualization and Integrated Discovery (DAVID, version 6.7, http://david.abcc.ncifcrf.gov/) (46,47) or Search Tool for the Retrieval of Interacting Genes (STRING; version 9.0; http://string-db.org) (48). Genes with a false discovery rate of ≤0.05 and P<0.05 were identified as enriched in the target genes. Then, a functional network of GO analysis was constructed using Cytoscape (version 2.8; http://cytoscape.org) (49).

The interaction pairs of target genes were additionally analysed using STRING version 9.0, and the interaction data was downloaded and analysed as described (50). A combined score >0.4 was selected as a threshold in order to construct the PPI network.

Additional analysis of miR-642b-3p and target genes in NSCLC from TCGA. TCGA (http://cancergenome.nih.gov/) is a collection of RNA sequencing, miRNA sequencing, exome sequencing, single nucleotide polymorphism array and DNA methylation data (51). TCGA may also be used to analyse clinical parameters and complicated cancer genomics (52,53). In the present study, raw data from RNASeq version 2 (54,55) in lung adenocarcinoma and squamous cell carcinoma for miR-642b and the 6 target genes (ZNF350, HNRNPU,
Table I. The top 5 GO functional annotation for the target genes of miR-642b-3p.

### A. Biological processes

| GO ID   | GO term                             | Count in network | FDR    | Gene symbol (top 30 genes)                                                                 |
|---------|-------------------------------------|------------------|--------|------------------------------------------------------------------------------------------|
| GO.0007275 | Multicellular organism development | 184              | 0.000122 | ABCA12, AB11, ADAR, ADRBK1, AGPAT5, AHR, AK4, AMBN, ANKRD1, ANKRD17, ARL6, ASB2, ATP8B1, ATXN3, BBS4, BCL11B, BCOR, BHLHB9, BMP3, CACNA1G, CALM1, CAMSAP1, CASQ1, CCK, CCNA2, CD109, CDH22, CDK5R2, CDKN1A |
| GO.0048731 | System development                  | 165              | 0.000122 | ABCA12, ABI1, ADAR, ADRBK1, AGPAT5, AHR, AK4, AMBN, AMHR2, ANKRD1, ANKRD17, ARL6, ASB2, ATP8B1, ATXN3, BBS4, BCL11B, BCOR, BHLHB9, BMP3, CACNA1G, CALM1, CAMSAP1, CASQ1, CCK, CCNA2, CD109, CDH22, CDK5R2, CDKN1A |
| GO.0008152 | Metabolic process                  | 353              | 0.000356 | ABCA12, ABHD10, ABHD2, ABI1, ABRA, ADAM22, ADAR, ADORA2B, ADRBK1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, AMHR2, ANGPT1, ANKRD1, ARSD, ASB2, ASCL1, ATAD1, ATG10, ATG12, ATP9A, B4GALT4, BAZ1A, BBS4, BCL11B, BCLAF1, BCOR |
| GO.0009893 | Positive regulation of metabolic process | 159          | 0.000356 | ABI1, ACAP2, ADAR, ADRBK1, AFF1, ANKRD1, ANKRD6, APP, ARHGAP18, ARHGAP31, ARHGAP6, ARHGEF37, ASB2, ASCL1, ATAD1, ATG10, ATXN3, BCLAF1, CALM1, CAND2, CARD8, CASP10, CCK, CCNA2, CCPG1, CDC25B, CDK5R2, CDKN1A, CENPE, CHRNA7 |
| GO.0042325 | Regulation of phosphorylation      | 75               | 0.000356 | ABI1, ADAR, ADORA2B, ANKRD6, APP, BMP3, CALM1, CCK, CCNA2, CD109, CDC25B, CDKN1A, CENPE, CHRNA7, CISH, CREBL2, DNAJC27, EIF2AK2, EPGN, EPHA7, EPHB1, FAM129A, FZD1, FZD4, GAB1, GDF6, GMFB, GRM1, HIPK3, IBTK |

### B. Cellular components

| GO ID   | GO term                           | Count in network | FDR    | Gene symbol (top 30 genes)                                                                 |
|---------|------------------------------------|------------------|--------|------------------------------------------------------------------------------------------|
| GO.0005622 | Intracellular                     | 470              | 3.88E-05 | ABCA12, ABHD10, ABI1, ABRA, ACAP2, ADAR, ADORA2B, ADRBK1, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, ANKRD1, ANKRD17, ANKRD6, ANKS1B, ANO5, ANTXR2, APP, ARHGAP18, ARHGAP31, ARHGAP6, ARHGEF37, ARS2, ASB2, ASC1L, ATG10 |
| GO.0043227 | Membrane-bound organelle          | 423              | 0.000126 | ABCA12, ABHD10, ABI1, ACAP2, ADAR, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, AMOTL2, ANGPT1, ANKRD1, ANKRD17, ANKRD6, ANKS1B, ANO5, ANTXR2, AP1S3, APP, ARL6, ARSD, ASCL1, ASTN2, ATG12, ATP8B1, ATP9A, ATXN3 |
Table I. Continued.

### B. Cellular components

| GO ID     | GO term                        | Count in network | FDR     | Gene symbol (top 30 genes)                                                                 |
|-----------|--------------------------------|------------------|---------|------------------------------------------------------------------------------------------|
| GO.0044424| Intracellular part              | 455              | 0.000126| ABCA12, ABHD10, ABI1, ABRA, ACAP2, ADAR, ADBK1, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, ANKR6, ANKS1B, ANO5, ANTXR2, APP, ARHGAP18, ARHGAP31, ARHGAP6, ARHGEF37, ARSD, ASB2, ASC1, ATG10 |
| GO.0043226| Organelle                      | 439              | 0.00018 | ABCA12, ABHD10, ABI1, ABRA, ACAP2, ADAR, ADBK1, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, AMOTL2, ANGPT1, ANKR6, ANKS1B, ANTXR2, APP, ARHGAP6, ARL6, ARSD, ASC1, ATG10 |
| GO.0043229| Intracellular organelle        | 411              | 0.000197| ABCA12, ABHD10, ABI1, ABRA, ACAP2, ADAR, ADBK1, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, AMOTL2, ANKRD1, ANKR6, ANKS1B, ANTOX2, AP1S3, APP, ARHGAP6, ARL6, ARSD, ASC1, ATG10 |

### C. Molecular functions

| GO ID     | GO term                         | Count in network | FDR     | Gene symbol (top 30 genes)                          |
|-----------|---------------------------------|------------------|---------|-----------------------------------------------------|
| GO.0005488| Binding                          | 392              | 0.00069 | ABCA12, ABI1, ABRA, ACAP2, ADAR, ADBK1, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, AMBN, AMHR2, ANGPT1, ANKMY1, ANKR6, ANKS1B, ANTXR2, APP, ARHGAP6, ARL6, ARSD, ATAD1, ATP8B1, ATP9A, ATXN3, B4GALT4, BAIA3P, BAZ1A |
| GO.0003674| Molecular function               | 456              | 0.000857| ABCA12, ABHD10, ABHD2, ACAP2, ADAR, ADORA2B, ADBK1, AFF1, AFF4, AGPAT5, AHR, AK4, AKAP4, ALDH4A1, AMBN, AMGPT1, ANKMY1, ANKR6, ANKS1B, ANTXR2, APP, ARHGAP6, ARHGEF37, ARL6, ARSD |
| GO.0005515| Protein binding                 | 200              | 0.000857| ABCA12, ABI1, ABRA, ADAM22, ADAMTS8, ADBK1, AHR, AKAP4, ALDH4A1, AMBN, AMGPT1, ANKRD1, ANKR6, ANKS1B, APP, ARHGAP6, ASC1, ATXN3, BAIAP3, BAZ2A, BBS4, BCO, BHLHR, BID2, BMP3, C18orf42, CACNA1B, CACNA1G, CALM1, CAM1SAP1, CARD8 |
| GO.0004705| JUN kinase activity             | 3                | 0.0274  | MAPK10, MAPK8, MAPK9                                |
| GO.0061578| Lys63-specific deubiquitinase activity | 3        | 0.0274  | ATXN3, CYLD, YOD1                                  |

GO, Gene Ontology; FDR, false discovery rate.
HMGB1, PDE4D, SYNCRIP and BHLHB9) were extracted from TCGA. The expression of miR-642b and the target genes in each case was subsequently calculated according to the distribution of exon reads.

Statistical analysis. SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) was used for statistical analysis. An unpaired Student's t-test was used for comparing the expression of miR-642b-3p and its target genes in lung adenocarcinoma and squamous cell carcinoma. The association between HOXA11-AS, miR-642b-3p and target genes were evaluated using Spearman's test. The association between gene expression and clinical diagnostic values was analysed using receiver operating characteristic curves. A Kaplan-Meier survival analysis was used to produce survival curves. P<0.05 was considered to indicate a statistically significant difference (two-tailed).

Results

miR-642b-3p profiling was associated with lncRNA HOXA11-AS. The transfection efficiency was ~100%, and the knockdown efficiency of HOXA11-AS in NSCLC cell lines was >75%, as determined by a reverse transcription-quantitative polymerase chain reaction (RT-qPCR; data not presented). Following the knockdown of HOXA11-AS, miR-642b-3p was significantly downregulated in A549 NSCLC cells (fold-change=0.355 and P=0.008).

miRNA target prediction. In the present study, four miRNA target prediction algorithms (miRDB, mirTarBase, TargetScan and DIANA-microT) were used to identify the target genes of miR-642b-3p. Venn diagrams were generated in order to analyse and compare the candidate genes. Amongst these target genes, 705 genes (including ZNF350, MAPK8, ASTN2 and YOD1) that were predicted by >2 algorithms were selected and these genes were used for GO and pathway analyses.

GO and pathway analysis and construction of a PPI network. The GO analysis was performed at the BP, CC and MF levels. The top 5 GO functional annotations for the target genes of miR-642b are presented in Table I. GO analysis indicated the significant functional groups, including multicellular organism development, intracellular part and molecular function. To further elucidate the relevant functions of the target genes, a functional network was constructed based on the GO analysis using Cytoscape (Fig. 1).

Using the online tools DAVID or STRING, the KEGG analysis demonstrated that the target genes may be involved in different pathways, including the avian erythroblastosis oncogene B2 signalling pathway, RIG-I-like receptor signalling pathway or mitogen-activated protein kinases (MAPK) signalling pathway (data not shown), with the false discovery rate value >0.05. Thus, perform further analyses on these pathways from KEGG were not performed.

Additionally, the PPI network was constructed using STRING, and a total of 1,228 PPI pairs with a combined score of >0.4 were selected. The map of the PPI network is presented in Fig. 2. The number of nodes was 700, accounting for 99.30% of all target genes. The clustering coefficient of the PPI network was 0.626. RAN binding protein 2 (degree=40) had the highest degree of interactions in the PPI network. A sub-network of 172 PPI pairs (with degree >15) was selected for further analyses (Fig. 3).

Supplementary information from TCGA database. In order to reveal the association between HOXA11-AS and NSCLC, a clinical study was performed using the raw data in TCGA. It was revealed that HOXA11-AS was upregulated in lung adenocarcinoma and squamous cell carcinoma compared with non-cancerous lung tissues (P<0.0001; Fig. 4A and B). The ROC curve revealed that the area under curve (AUC) of HOXA11-AS was 0.700 (95% confidence interval (CI), 0.636-0.764; P=0.003) for patients with lung adenocarcinoma and 0.964 (95% CI, 0.946-0.981; P<0.0001) for patients with squamous cell carcinoma, which may gain a moderate or high diagnostic value of HOXA11-AS level in lung cancer (Fig. 4C and D).

To elucidate the relationships between miR-642b and NSCLC, a clinical study was performed using the primary data in TCGA. It was revealed that miR-642b was significantly upregulated in lung adenocarcinoma (P=0.0001) and non-significantly upregulated in squamous cell carcinoma (P=0.348) compared with non-cancerous lung tissues (Fig. 5A and B). The relationship between miR-642b and the prognosis of NSCLC was also investigated, and
it was revealed that the high expression of miR-642b was associated with the overall survival of patients with adenocarcinoma (108.56±25.23 vs. 79.51±8.75; P=0.018; Fig. 5C), which indicated that miR-642b may influence the prognosis of adenocarcinoma. The correlation between HOXA11-AS and miR-642b was also investigated, but no significant correlation was revealed in lung adenocarcinoma (r=−0.047, P=0.507; data not shown) and squamous cell carcinoma (r=0.123, P=0.148; data not shown) partly due to the fact that only 203 lung patients with adenocarcinoma and 140 patients with squamous cell carcinoma were included in the data from TCGA.

For target gene prediction, six target genes (ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP and BHLHB9) of miR-642b-3p were identified by all four prediction algorithms. Then, further analyses were performed in order to determine whether the expressions of these genes were associated with NSCLC, based on the data from TCGA. It was revealed that the expressions of HNRNPU, SYNCRIP and BHLHB9 were upregulated in lung adenocarcinoma and squamous cell carcinoma, whereas PDE4D was significantly downregulated in lung adenocarcinoma and squamous cell carcinoma (P<0.001). For the remaining two genes (ZNF350 and HMGB1), it was revealed that ZNF350 was upregulated in lung adenocarcinoma and significantly downregulated in lung squamous cell carcinoma (P<0.0001), whereas HMGB1 was significantly downregulated in lung adenocarcinoma and significantly upregulated in lung squamous cell carcinoma (P<0.05, Figs. 6 and 7). Subsequently, the relationship between these genes and overall survival or disease-free survival of NSCLC was investigated. It was revealed that in lung squamous cell carcinoma, ZNF350 and PDE4D were significantly associated with disease-free survival (P<0.05). In lung adenocarcinoma, it was discovered that HNRNPU was associated with overall survival and disease-free survival (P<0.05), and PDE4D and HMGB1 were related to disease-free survival (P<0.05), and BHLHB9 was only
associated with overall survival (P<0.05, Fig. 8). Additionally, the correlation between HOXA11-AS expression and the 6 target genes was analysed, and a weak negative correlation was revealed between HOXA11-AS and PDE4D or ZNF350 in lung adenocarcinoma and squamous cell carcinoma, whereas HNRNPU and SYNCRIP were positively correlated with HOXA11-AS. BHLHB9 and HMGB1 were revealed to have a weak positive correlation with HOX11-AS in lung adenocarcinoma, and a weak negative correlation with HOX11-AS in squamous cell carcinoma (Table II).

Amongst these results, PDE4D was downregulated in lung adenocarcinoma and squamous cell carcinoma, and a weak negative correlation was revealed between HOXA11-AS and PDE4D. Furthermore, the diagnostic value of PDE4D level in lung cancer was assessed and it was revealed that the AUC of PDE4D was 0.905 (95% CI, 0.879-0.931) for patients with lung adenocarcinoma and 0.665 (95% CI, 0.606-0.725) for patients with squamous cell carcinoma (P<0.0001; Fig. 9).

Discussion

LncRNAs are non-protein-coding RNA molecules and the length of IncRNAs varies from 200 nucleotides to 100 kb (20). Numerous IncRNAs have been confirmed to have important functions in transcriptional regulation, epigenetic gene regulation or disease development (13-15). Additionally, IncRNAs have been associated with the tumorigenesis and progression of NSCLCs. To date, different IncRNAs have been reported to perform different functions in NSCLC, including IncRNA AK126698, GAS5-AS1 and TUSC7, which may be associated with cell proliferation, metastasis and a poor prognosis in NSCLC (56-58). Multiple previous reports have demonstrated...
that lncRNAs function in lung cancer by regulating the expression of miRNAs (23-25,59). HOXA11-AS is a member of the homeobox family of genes. To the best of our knowledge, only two previous studies have reported the relationship between

Figure 4. Differential expression and ROC curve of HOXA11-AS in lung adenocarcinoma and squamous cell carcinoma based on The Cancer Genome Atlas database. The differential expression of HOXA11-AS in (A) lung adenocarcinoma and (B) squamous cell carcinoma. The ROC curve of HOXA11-AS in (C) lung adenocarcinoma and (D) squamous cell carcinoma. ROC, receiving operator characteristic; HOXA11-AS, HOXA11 antisense RNA.

Figure 5. Differential expression of miR-642b in lung adenocarcinoma and squamous cell carcinoma based on the Cancer Genome Atlas database. The expression of miR-642b between normal lung and (A) lung adenocarcinoma cells or (B) lung squamous cell carcinoma cells. (C) Kaplan-Meier curves for miR-642b expression in lung adenocarcinoma. miR, microRNA.
Figure 6. Differential expression of ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP, and BHLHB9 between lung adenocarcinoma and normal lung tissues based on the Cancer Genome Atlas database. Differential expression of (A) ZNF350, (B) HNRNPU, (C) HMGB1, (D) PDE4D, (E) SYNCRIP and (F) BHLHB9. ZNF350, zinc finger protein 350; HNRNPU, heterogeneous nuclear ribonucleoprotein U; HMGB1, high mobility group box 1; PDE4D, phosphodiesterase 4D; SYNCRIP, synaptotagmin binding cytoplasmic RNA interacting protein; BHLHB9, basic helix-loop-helix family member B9.
Figure 7. Differential expression of ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP and BHLHB9 between lung squamous cell carcinoma and normal lung tissues based on the Cancer Genome Atlas database. Differential expression of (A) ZNF350, (B) HNRNPU, (C) HMGB1, (D) PDE4D, (E) SYNCRIP and (F) BHLHB9. ZNF350, zinc finger protein 350; HNRNPU, heterogeneous nuclear ribonucleoprotein U; HMGB1, high mobility group box 1; PDE4D, phosphodiesterase 4D; SYNCRIP, synaptotagmin binding cytoplasmic RNA interacting protein; BHLHB9, basic helix-loop-helix family member B9.
HOXA11-AS and cancer. Richards et al (9) conducted various functional experiments and analysed genome-wide data, and revealed that HOXA11-AS may inhibit the oncogenic phenotype of epithelial ovarian cancer, which may be enhanced by the T allele. Wang et al (10) used a high-throughput microarray and gene set enrichment analysis to demonstrate...
that HOXA11-AS may have a growth-promoting function in glioma via the regulation of cell cycle progression. However, the specific pathogenesis of HOXA11-AS in NSCLC remains unclear. Thus, the present study was designed using A549 cells to investigate the expression profile changes of miR-642b-3p following HOXA11-AS knockdown and the potential molecular mechanisms of HOXA11-AS in NSCLC.

In the present study, miR-642b-3p and its target genes (ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP, BHLHB9) were analysed. To the best of our knowledge, only one previous study has reported on the relationship between miR-642b-3p and cancer. Hamam et al (60) revealed that miR-642b-3p was upregulated in breast cancer, and miR-642b-3p in combination with eight other upregulated miRNAs may be used for the early detection of breast cancer. Similarly, to this previous study, miR-642b-3p was upregulated in lung adenocarcinoma and squamous cell carcinoma, but the specific association between miR-642b-3p and NSCLC remains to be verified by functional experiments. Then, six target genes of miR-642b-3p were investigated and it was revealed that all six target genes were differentially expressed in lung adenocarcinoma and squamous cell carcinoma. Additionally, miR-642b-3p, ZNF350, HNRNPU, HMGB1, PDE4D and BHLHB9 were associated with the overall survival or disease-free survival of patients with lung adenocarcinoma or patients with squamous cell carcinoma based on TCGA database. Numerous previous studies have confirmed the association between these target genes and NSCLC. Deng et al (61) used a western blot analysis to determine that miR-193a-3p may inhibit the metastasis of lung cancer cells by de-regulating the expression of HNRNPU and other tumour-associated proteins. Numerous studies have assessed HMGB1. HMGB1 has been associated with cell migration, invasion, apoptosis, sensitivity to chemotherapy drugs and the prognosis of NSCLC (62-64). Karachaliou et al (65) revealed that PDE4D was associated with resistant epidermal growth factor receptor (EGFR)-mutant cancer cell lines, and the combination of EGFR tyrosine kinase inhibitors with PDE4D inhibitors may be an effective therapy for patients with EGFR-mutant NSCLC.

In the findings of the present study, PDE4D was downregulated in lung adenocarcinoma and squamous cell carcinoma, and a weak negative association was established between HOXA11-AS and PDE4D. Additionally, PDE4D was associated with disease-free survival of lung adenocarcinoma and squamous cell carcinoma, which indicated that PDE4D may influence the prognosis of adenocarcinoma. Therefore, the present study hypothesized that miR-642b-3p, which is regulated by lncRNA HOXA11-AS and targets PDE4D, may have a function in NSCLC tumorigenesis and deterioration.

Numerous studies have demonstrated that PDE4D may function in cancer via different pathways, including the EGFR/phosphoinositide 3-kinase/protein kinase B signalling pathway, MAPK pathway and Hedgehog pathway (66-68). However, further exploration is required to clarify the potential molecular mechanisms of PDE4D in NSCLC.

Additionally, there are limitations in the present study. The present study was conducted based on several online tools, including DAVID, STRING, Cytoscape and TCGA, which may only be used for reference. Furthermore, the specific molecular mechanisms of miR-642b-3p and genes it is associated with,

| Gene name                  | Lung adenocarcinoma | Squamous cell carcinoma |
|----------------------------|---------------------|-------------------------|
| Heterogeneous ribonucleoprotein U | R-value: -0.004, P-value: 0.949 | R-value: -0.067, P-value: 0.639 |
| Zinc-finger protein 350    | R-value: -0.004, P-value: 0.949 | R-value: -0.067, P-value: 0.639 |
| Phosphodiesterase 4D       | R-value: -0.012, P-value: 0.049 | R-value: -0.068, P-value: 0.068 |
| Basic helix-loop-helix family member B9 | R-value: -0.0001, P-value: 0.187 | R-value: -0.0001, P-value: 0.188 |
| Synaptotagmin-binding Zinc finger nuclear protein 350 | R-value: 0.307, P-value: 0.041 | R-value: 0.128, P-value: 0.093 |
| Cytoplasmic RNA interacting protein | R-value: 0.303, P-value: 0.041 | R-value: 0.128, P-value: 0.093 |
require further elucidation through functional experiments. To assess this hypothesis, a series of experiments may be designed using various molecule, cell, tissue and animal models (including RT-qPCR, western blot analysis, proliferation, invasion and metastasis assays, dual luciferase reporter assay, RNA pull-down, chromatin immunoprecipitation, chicken embryo chorioallantoic membrane and nude mouse models). The present study, which focused on the function of the HOXA11-AS/miR-642b-3p/PDE4D axis, suggests a novel target for a clinical therapeutic strategy for NSCLC. In conclusion, HOXA11-AS may influence the expression of miR-642b-3p in the different biological processes of NSCLC by targeting the expression of PDE4D or other target genes. Raw data from TCGA confirmed the oncogenic function of miR-642b in lung adenocarcinoma and squamous cell carcinoma. The findings of the present study lay the foundation for future studies on the relationship between HOXA11-AS and the potential molecular mechanisms in NSCLC tumorigenesis and progression.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant nos. NSFC81560469 and NSFC81360327), the Scientific Research Project of Basic Ability Promoting for Middle Age and Youth Teachers of Guangxi Universities (grant no. KY2016YB077), the Natural Science Foundation of Guangxi, China (grant no. 2015GXNSFFA139009) and the Guanxi Provincial Health Bureau Scientific Research Project (grant nos. Z2013201 and Z2014055).

References

1. Xu YJ, Du Y and Fan Y: Long noncoding RNAs in lung cancer: What we know in 2015. Clin Transl Oncol 18: 660-665, 2016.
2. Kang CG, Lee HJ, Kim SH and Lee EO: Zerumbone suppresses osteopontin-induced cell invasion through inhibiting the FAK/AKT/ROCK pathway in human non-small cell lung cancer A549 cells. J Nat Prod 79: 156-160, 2016.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
4. Xu G, Chen J, Pan Q, Huang K, Pan J, Zhang W, Chen J, Yu F, Zhou T and Wang Y: Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS One 9: e104044, 2014.
5. Choe C, Shin YS, Kim C, Choi SJ, Lee J, Kim SY, Cho YB and Kim J: Crossstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. Onco Targets Ther 8: 3665-3678, 2015.
6. Jemal A, Siegel R, D'Heurtore M and Ward E: Global cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
7. Yeo Y, Lee JS, Kim J, Park S, Kim H, Oh S, Park J, Kang J and Lee H: HOXA11-AS promotes progression of head and neck squamous cell carcinoma by acting via BMI1, promotes an altered cell cycle transition in the malignant transformation of HBE cells induced by cigarette smoke extract. Toxicol Appl Pharmacol 304: 30-41, 2016.
8. Jiao W, He HJ, Yang XQ, Sun X, Hu Y, Geng L, Wang J, Zhang W, Zeng Z, Zhang J, Jiang Z, Shu Z and Ge HJ: The H19 lincRNA is a developmental reservoir for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci 20: 2253-2255, 2016.
9. Salmena L, Poliseno L, Tay T, Kats L and Pandolfo P: A ceRNA hypothesis: The rosetta stone of a hidden RNA language? Cell 146: 353-358, 2011.
10. Sun C, Li S, Zhang F, Xi Y, Wang L, Bi Y and Li D: Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. Oncotarget 7: 51784-51814, 2016.
11. Lu L, Xu H, Luo F, Liu X, Lu X, Yang Q, Xue J, Chen C, Shi L and Liu Q: Epigenetic silencing of miR-218 by the IncRNA CCAT1, acting via BMI1, promotes an altered cell cycle transition in the malignant transformation of HBE cells induced by cigarette smoke extract. Toxicol Appl Pharmacol 304: 30-41, 2016.
12. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
13. Xu G, Chen J, Pan Q, Huang K, Pan J, Zhang W, Chen J, Yu F, Zhou T and Wang Y: Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS One 9: e104044, 2014.
14. Choe C, Shin YS, Kim C, Choi SJ, Lee J, Kim SY, Cho YB and Kim J: Crossstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. Onco Targets Ther 8: 3665-3678, 2015.
34. Lu YJ, Liu RY, Hu K and Wang Y: MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer. Tumour Biol 37: 12685-12695, 2016.

35. Xu X, Wang X, Fu B, Meng L and Zhang B: Differentially expressed genes and miRNAs in bladder carcinoma cell line 5637 and T24 detected by RNA sequencing. Int J Clin Exp Pathol 8: 12678-12687, 2015.

36. Li Q, Ge X, Xu X, Zhong Y and Qie Z: Comparison of the gene expression profiles between gallstones and gallbladder polyps. Int J Clin Exp Pathol 7: 8016-8023, 2014.

37. Jiang CM, Wang XY, Shu J, Yang WX, Fu P, Zhuang LL and Zhou GP: Analysis of differentially expressed genes based on microarray data of glioma. Int J Clin Exp Med 8: 17321-17332, 2015.

38. Chen L, Zhuo D, Chen J and Yuan H: Screening feature genes of lung carcinoma with DNA microarray analysis. Int J Clin Exp Med 8: 12161-12171, 2015.

39. Wang X: Improving microRNA target prediction by modeling with unambiguously identified microRNA-target pairs from CLIP-ligation studies. Bioinformatics 32: 1316-1322, 2016.

40. Wongs and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 43 (Database Issue): D146-D152, 2015.

41. Chou CH, Chang NW, Shreshtha S, Hsu SD, Lin YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, et al; miRTarBase 2016: Updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44: D239-D247, 2016.

42. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.

43. Pisansakounapoulou MD, Georgakis G, Kostoulas N, Vlachos IS, Vergoulis T, Rezcko M, Filippidis C, Dalamagas T and Hatzigeorgiou AG: DIANA-miRT web server v5.0: Service integration into miRNA functional analysis workflows. Nucleic Acids Res 41 (Web Server Issue): W169-W173, 2013.

44. Rezcko M, Maragkakis M, Alexiou P, Grosse I and Hatzigeorgiou AG: Functional microRNA targets in protein coding sequences. Bioinformatics 28: 771-776, 2012.

45. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29, 2000.

46. Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009.

47. Szklarczyk D, Morris JD, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45: D362-D368, 2017.

48. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504, 2003.

49. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al: STRING v9.1: Protein–protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41 (Database issue): D808-D815, 2013.

50. Bornstein S, Schmidt M, Choonoo G, Levin T, Gray J, Thomas CR Jr, Wong M and McWeeny S: IL-10 and integrin signaling pathways are associated with head and neck cancer progression. BMC Genomics 17: 38, 2016.

51. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404, 2012.

52. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pe1, 2013.

53. Li B, Ruotti V, Stewart RM, Thomson JA and Dewey CN: RNA-Seq gene expression estimation with read mapping uncertainty. Bioinformatics 26: 493-500, 2010.

54. Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, He X, Mieczkowski P, Grimm SA, Perou CM, et al: MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res 38: e178, 2010.

55. Wu Y, Lu C, Shi H, Shi X, Song Y and Liu B: Downregulation of the long non-coding RNA GASS-AS1 contributes to tumor metastasis in non-small cell lung cancer. Sci Rep 6: 31093, 2016.

56. Xu F, Li H, Liu C, Hu B, Li T and Wang Y: Long non-coding RNA AK126698 inhibits proliferation and migration of non-small cell lung cancer cells by targeting Frizzled-8 and suppressing Wnt/β-catenin signaling pathway. Onco Targets Ther 9: 3815-3827, 2016.

57. Wang Z, Jin Y, Ren H, Ma X, Wang B and Wang Y: Downregulation of the long non-coding RNA TUSC7 promotes NSCLC cell proliferation and correlates with poor prognosis. Am J Transl Res 8: 680-687, 2016.

58. You J, Zhang Y, Liu B, Li Y, Fang N, Zu L, Li X and Zhou Q: MicroRNA-49A inhibits cell growth in lung cancer and regulates long non-coding RNA nuclear enriched abundant transcript 1. Indian J Cancer 51 (Suppl 3): e77-e81, 2014.

59. Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Alahmash A and Alajezi NM: microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep 6: 25997, 2016.

60. Deng W, Yan M, Yu T, Ge H, Lin H, Li J, Liu Y, Geng Q, Zhu M, Liu L, et al: Quantitative proteomic analysis of the metastasis-inhibitory mechanism of miR-193a-3p in non-small cell lung cancer. Cell Physiol Biochem 35: 1677-1688, 2015.

61. Zhang C, Ge S, Hu C, Yang N and Zhang J: MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 45: 1055-1061, 2013.

62. Zhang R, Li Y, Wang Z, Chen L, Dong X and Nie X: Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis. Tumor Biol 36: 8585-8592, 2015.

63. Feng A, Tu Z and Yin B: The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. Oncotarget 7: 20507-20519, 2016.

64. Karachaliou N, Codony-Serrat J, Teixidó C, Piloto S, Drozdowskij A, Codony-Serrat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, et al: BIM and mT OR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep 5: 17499, 2015.

65. Xu T, Wu S, Yuan Y, Yan G and Xiao D: Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway. Oncol Lett 8: 2110-2116, 2014.

66. Powers GL, Hammer KD, Domenech M, Frantskevich K, Malinowski RL, Bushman W, Beebe DJ and Marker PC: Phosphodiesterase 4D inhibitors limit prostate cancer growth potential. Mol Cancer Res 13: 149-160, 2015.

67. Ge X, Milenkovic L, Suyama K, Hartl T, Purzner T, Winans A, Drozdowskyj A, Codony-Serrat C, Giménez-Capitán A, Malinowski RL, Bushman W, Beebe DJ and Marker PC: Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma. Elite 4, 2015.